Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
A phase 1/2 trial of Acalabrutinib, Rituximab, Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Acerta Pharma BV, active and no longer recruiting.
Overview
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT02180711 by Acerta Pharma BV, with 113 participants enrolled, started 2014-12-29 and due to reach its primary completion in 2023-08-25. Interventions recorded: acalabrutinib, rituximab (IV), Lenalidomide. Conditions listed: Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
Shares Lenalidomide, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Shares Lenalidomide, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialStudy of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl
Shares Lenalidomide, Rituximab, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.